Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Courses
  4. ESMO Advanced Course on Role of CDK4/6 Inhibitors in Hormone Receptor Positive HER2 Negative in Breast Cancer 2024: Jeddah

Session 1 – CDK4-6 inhibitors in early breast cancer

Incorporating CDK 4-6 inhibitors in patients with high-risk HR positive/ HER2 negative early breast cancer: Challenging clinical scenarios with the use of PARP inhibitors and immune-checkpoint inhibitors

Date

07 Sep 2024

Session

Session 1 – CDK4-6 inhibitors in early breast cancer

Topics

Targeted Therapy

Tumour Site

Breast Cancer

Presenters

D. Trapani, IT

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.